Clinical Trial Update: Sativex for Treatment of Chemotherapy Induced Neuropathic Pain [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Sativex (nabiximol) for chemotherapy-induced peripheral neuropathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Peripheral Neuropathy

Drugs mentioned

• Sativex (nabiximol)

Snippet

Sponsor: Mary Lynch | Conditions: Neuropathic Pain | Phase 3 | Status: COMPLETED